Aclaris Therapeutics, Inc. 8-K

What Happened
Aclaris Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued May 7, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 7, 2026 (Form 8‑K, Item 2.02).
• Reporting period: quarter ended March 31, 2026.
• Exhibit 99.1: press release with the announced results was furnished with the Form 8‑K.
• Exhibit 104: cover page provided in Inline XBRL format.
• Report signed on behalf of Aclaris by CFO Kevin Balthaser.

Why It Matters
This filing makes the company’s quarterly financial results publicly available; investors should read the furnished press release for the specific earnings, revenue, cash flow, and any guidance or management commentary. Because the 8‑K furnishes (rather than files) the release under General Instruction B.2, investors should check the press release text or the company’s SEC filings for the full numeric details and any related disclosures.